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Abstract 
Background: 
The success rate of in vitro fertilisation remains modest and many patients undergo multiple 
treatment cycles. Previous studies suggested in vitro fertilisation outcome could be improved in 
patients who have experienced recurrent implantation failure if hysteroscopy was performed before 
starting a treatment cycle. However, those studies were of limited quality and a definitive randomised 
trial was needed.  
Methods: 
The TROPHY trial was a single-blind multi-centre randomised controlled trial conducted in eight 
hospitals in four European countries. Women who had normal ultrasound of the uterine cavity and 
history of two to four failed in vitro fertilisation cycles were randomised to have either outpatient 
hysteroscopy or no hysteroscopy in the month before starting the subsequent treatment cycle. The trial 
used allocation concealment and minimisation for key prognostic variables, including age, body mass 
index and basal follicle stimulating hormone level. The primary outcome was live birth rate. 
Secondary outcomes were pregnancy, implantation and miscarriage rates and hysteroscopy findings. 
The trial was registered on the ISRCTN Registry (#ISRCTN35859078). 
Findings:  
Seven hundred and two women younger than 38 years were randomly assigned between January 2010 
and December 2013; 350 allocated to the outpatient hysteroscopy group and 352 to the control group. 
The live birth rate after in vitro fertilisation was 29% (102/350) in the hysteroscopy group and 29% 
(102/352) in the control group (relative risk [RR] 1·0; 95% confidence interval [CI] 0·79, 1·25, 
P=0·96). Hysteroscopy identified uterine abnormalities in 26% (85/323) of women. No hysteroscopy-
related complications occurred. There were no significant differences in the pregnancy, implantation 
or miscarriage rates. 
Interpretation:  
Outpatient hysteroscopy before in vitro fertilisation treatment in women with normal ultrasound of the 
uterine cavity and a history of two to four failed in vitro fertilisation treatment cycles does not 
improve the live birth rate. 
Funding: 
The trial was funded by the European Society of Human Reproduction and Embryology, and the 
European Society for Gynaecological Endoscopy.  
(word count = 300) 
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Introduction: 
In vitro fertilisation treatment is utilised widely. In 2010, over 700,000 treatment cycles have been 
reported in the United States and Europe alone and the number of cycles is expanding steadily.1,2 
Despite technological advances, the live birth rate per cycle is modest and many patients remain 
infertile after multiple in vitro fertilisation attempts. Recurrent implantation failure, defined as two or 
more failed in vitro fertilisation embryo transfer cycles, 3 is distressing to patients and challenging to 
clinicians. 4 The aetiology of recurrent implantation failure could be attributed to either embryonic or 
uterine factors. Several interventions have been proposed to improve in vitro fertilisation outcome 
after multiple failed attempts, of which only few are evidence-based. 5,6  
Intra-uterine pathology has been reported in up to 25% of infertile women having in vitro fertilisation 
treatment and as high as 50% of women with recurrent implantation failure, leading to suggestion that 
correction of such pathology could improve treatment outcome.7,8 Hysteroscopy allows visual 
assessment of the cervical canal and uterine cavity and provides the opportunity to perform corrective 
surgery in the same setting. 8-11 Routine outpatient hysteroscopy before starting in vitro fertilisation 
treatment has been proposed as a tool to confirm or restore normality of the uterine cavity and 
improve in vitro fertilisation treatment outcome. 12-14 
A systematic review of published studies has suggested that outpatient hysteroscopy performed in the 
menstrual cycle preceding an in vitro fertilisation treatment cycle could significantly increase the 
clinical pregnancy rate in women who had previously experienced recurrent implantation failure, even 
when no hysteroscopic abnormality was detected. 15 However, the review included five single-centre 
heterogeneous studies, of which only two were randomised trials lacking clear description of the 
method of randomisation, allocation concealment, adjustment for important confounding variables 
and sufficient live birth data, and thus suffering from a risk of bias. Therefore, conducting a robust 
multi-centre randomised study was needed to inform clinical practice. 13,15  
The aim of our study was to investigate whether outpatient hysteroscopy performed in the month 
before starting an in vitro fertilisation treatment cycle in women who had experienced two to four 
failed in vitro fertilisation treatment cycles could improve the treatment outcome. We conducted a 
multi-country multi-centre allocation concealed single-blind randomised controlled trial comparing 
the live birth rate after in vitro fertilisation with or without prior outpatient hysteroscopy (The 
TROPHY Trial). 16 
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Methods 
Study design: 
The TROPHY study was a multi-centre allocation concealed single-blind randomised controlled trial 
conducted between January 2010 and December 2013 in eight European hospitals located in the 
United Kingdom (3 sites), Belgium (2 sites), Italy (2 sites) and the Czech Republic (1 site). The trial 
was registered on the ISRCTN Registry (#ISRCTN35859078). The study was approved by the United 
Kingdom Research Ethics Committee (reference: 09/H0804/32), and the ethics committees of 
participating hospitals. 
Participants: 
Women below the age of 38 years of age who had a normal transvaginal ultrasound appearance of the 
uterine cavity and previously had between two to four in vitro fertilisation treatment cycles ending in 
an embryo transfer but no pregnancy and who were undergoing a further treatment cycle of in vitro 
fertilisation were eligible to participate in the trial. Women aged 37 years were eligible to participate 
only if they had at least 8 oocytes retrieved in the previous in vitro fertilisation cycle. All participants 
gave written informed consent and were included in the study only once. 
Women were excluded if they had less than two or more than four failed in vitro fertilisation cycles 
ending in an embryo transfer, a hysteroscopy within two months before randomisation, submucous or 
intramural uterine fibroids diagnosed by ultrasound to be distorting the uterine cavity, untreated tubal 
hydrosalpinges, or a body mass index above 35 kg/m2. 
Randomisation and masking: 
Participants were randomised to receive either outpatient hysteroscopy or no hysteroscopy online via 
a secure internet facility in a 1:1 ratio through a third party independent Integrated Trial Management 
System (MedSciNet Clinical Trial Framework). A minimisation procedure using a computer-based 
algorithm was used to avoid chance imbalances, within the whole study participants and in each 
participating centre, in important prognostic variables including age (≤30 or 31-37 years), body mass 
index (<30 or 30-35 kg/m2), number of previous failed in vitro fertilisation treatment cycles (2 or 3-4) 
and basal follicle stimulation hormone level (<10 or ≥10 iu/L). The randomised allocation was not 
given until eligibility and minimisation data had been completed. The trial was single-blind, where the 
embryologists involved in the embryo transfer procedures were blinded to patient’s allocation in the 
trial. The physicians performing the embryo transfer procedure were not blinded to patient allocation 
and had the hysteroscopy findings accessible. 
Procedures: 
Women randomised to outpatient hysteroscopy had the procedure performed within 14 days of 
menstruation and started the in vitro fertilisation treatment cycle in the following month according to 
a standard in vitro fertilisation protocol.17 Women randomised to the control group started the in vitro 
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fertilisation treatment cycle according to a standard in vitro fertilisation protocol without undergoing 
hysteroscopy.  
Outpatient hysteroscopy:  
Outpatient hysteroscopy was performed using a rigid 30° view 2.9 mm diameter hysteroscope with an 
atraumatic tip (TROPHYscope, Karl Storz, Tuttlingen, Germany) in a vaginoscopic approach. 14,16,18 
The hysteroscope could be assembled with accessory sheaths in an active or passive position. Each 
hysteroscopy was started with the single-flow 2·9 mm instrument for inspection of the cervical canal 
and uterine cavity, and if necessary, the accessory diagnostic (3·7 mm) or operative (4·4 mm) sheath 
was moved forward to establish a double-flow mode and allow operative intervention using 5 French 
instruments (crocodile forceps, biopsy forceps and scissors). An isotonic solution (0.9% Normal 
saline or Ringer lactate) administered via a pressure-controlled pump or simple pressure cuff system 
was used to provide the lowest pressure required to distend the uterine cavity for adequate 
visualisation. No routine pre-operative analgesia, antibiotics, sedation or cervical preparation was 
used. A standardised protocol, data collection tool and clear description of possible abnormalities 
were provided to each participating centre.16After hysteroscopy, patients were observed in a recovery 
area before being allowed to leave the clinic.  
In vitro fertilisation protocol:  
The in vitro fertilisation treatment cycle was commenced in the menstrual cycle immediately 
following the outpatient hysteroscopy. The ovarian stimulation protocols used for the in vitro 
fertilisation treatment cycles were described previously.17 Briefly, follicle stimulating hormone 
injections were started at a dose of 150-450 IU daily for multi-follicular ovarian stimulation. Final 
oocyte maturation was induced using 5,000-10,000 IU of human chorionic gonadotrophin when at 
least two 18 mm follicles were seen on ultrasound scanning. Ultrasound-guided oocyte retrieval was 
performed 34-38 hours following human chorionic gonadotrophin administration. Progesterone 
supplementation was used for luteal phase support and continued for up to eight weeks gestation if 
pregnancy had occurred. Embryo development and quality after fertilisation were assessed until 
transfer or freezing.19 Between one and three embryos were transferred into the uterine cavity 
according to each participating centre’s protocol. 
Outcomes: 
The primary outcome was the live birth rate (after 24 weeks gestation). Secondary outcomes were 
pregnancy (defined as positive human chorionic gonadotrophin test using commercial urinary testing 
kit), clinical pregnancy (defined as the observation of fetal cardiac activity on ultrasound scan four or 
more weeks after embryo transfer), implantation (defined as the presence of an intra-uterine 
gestational sac on ultrasound scan four or more weeks after embryo transfer) and miscarriage (defined 
as pregnancy loss before 24 weeks gestation) rates, abnormal hysteroscopy findings and 
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hysteroscopy-related complications. The implantation rate was calculated as the number of gestational 
sacs seen on ultrasound scanning divided by the number of embryos transferred. 
Statistical Analysis: 
Number of participants 
It was calculated that to detect a minimally important difference of 10% increase in the live birth rate 
from 25% to 35%, for a double-sided alpha error of 5% and 80% power, it would be necessary to 
randomise 329 women each to the outpatient hysteroscopy and control groups (658 women in total). 
Assuming a drop-out rate of 5%, the number of participants required would be 694 in total.20 The 
baseline live birth rate of 25% and the minimally important difference of 10% were based 
conservatively on the results of the studies included in the published systematic review16 and 
following consultations with fertility practitioners. No replacement of trial subjects who had 
withdrawn from the study was planned as the analysis was performed according to intention-to-treat. 
Sample size calculations were carried out in Stata version 13·1 (Stata Corp, College Station, Texas, 
USA), following standard methods for two proportions without a continuity correction.  
Baseline and outcome data were summarised separately. For normally distributed continuous 
variables, data were summarised as means with standard deviations. For non-normally distributed 
variables, data were reported as medians and inter-quartile ranges [IQR]. Categorical baseline and 
dichotomous data were reported as absolute numbers and percentages. The statistical procedures used 
for comparisons depended on the nature of the data; for dichotomous outcomes we used risk ratios 
calculated using binomial regression with a log link, and for continuous outcomes we used t-test if the 
observations in each trial arm were normally or near-normally distributed (or could be transformed to 
normality using a log transformation). If there was a suspicion of non-normality, boot-strapping with 
500 replications was carried out as a sensitivity analysis. 
Sub-group analysis 
We gave emphasis to analysis within planned (a priori) sub-groups (namely normal versus abnormal 
hysteroscopic findings and analysis by receiving embryo transfer including receiving at least one top 
quality embryo19) with an interaction test. As sub-group analysis could suffer from false positive (due 
to multiplicity of comparisons) and false negative (due to reduced sample sizes) results, we 
determined the outcome of the trial in terms of the primary endpoint (live birth rate) and placed 
limited importance on sub-group analysis findings in relation to the overall findings. We hypothesised 
that outpatient hysteroscopy could be most beneficial in women who did not report a history of having 
hysteroscopy before randomisation, and used post-hoc sub-group analysis with an interaction test to 
assess the consistency of the intervention effect and for hypothesis generation only. 
Study Oversight: 
The TROPHY trial was conducted according to the Principles of Good Clinical Practice as defined in 
the Medicines for Human Use (Clinical Trials) Amended Regulations 2006, the Research Governance 
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Framework for Health & Social Care 2005 and the Data Protection Act. Trial oversight was provided 
by the Trial Steering Committee and an independent Data Safety Monitoring Committee. The Data 
Safety Monitoring Committee had independent members with clinical and statistical background, who 
had no conflict of interest relating to the two trial arms and no involvement in running any part of the 
trial. During the trial, the Data Safety Monitoring Committee reviewed unblinded outcome data for 
principal safety and efficacy end points. 
Role of the funding source: 
The European Society of Human Reproduction and Embryology and the European Society for 
Gynaecological Endoscopy provided funding for trial co-ordination and meetings. Karl Storz 
Company provided the hysteroscopy equipment for all centres and Tristel Solutions Limited 
(Snailwell, Cambridgeshire, United Kingdom) provided the equipment disinfecting systems for five of 
the eight participating centres. Neither the trial funders nor the medical products suppliers had any 
role in the study design, data collection, data analysis, data interpretation or writing of the report.  
 
Results:  
A total of 702 women were recruited to the TROPHY trial; 350 women to receive hysteroscopy and 
352 women to receive no hysteroscopy before starting the in vitro fertilisation (with or without 
intracytoplasmic sperm injection) treatment cycle. The baseline characteristics of the study population 
were comparable across the two study groups (Table 1). The participants’ flow in the study is shown 
in figure 1. 
 
In the hysteroscopy group, 323/350 (93%) women received outpatient hysteroscopy, one had saline 
hysterosonography instead at her request, and 26 did not have a hysteroscopy (Figure 1). Of the 323 
hysteroscopy procedures performed, no cavity access failure was encountered and one hysteroscopy 
was not completed due to insufficient visualisation. A cervical canal or uterine cavity abnormality was 
reported in 85 hysteroscopies (26%, Table 2). Of the 34 uterine cavity abnormalities detected, 15 were 
treated surgically including resection of eight endometrial polyps, four partial uterine septae, two 
submucosal fibroids and one T-shaped cavity. No surgical intervention was performed for dysmorphic 
(arcuate) uterine cavity (n=15), hemi-uterus (n=3) and one partial uterine septum. Four women in the 
control group had hysteroscopy at their request before starting the in vitro fertilisation treatment cycle. 
The median duration of the outpatient hysteroscopy procedure was seven minutes (IQR 5-10 minutes) 
and median duration to discharge after the procedure was 10 minutes (IQR 6-30 minutes). No 
hysteroscopy-related complications were reported.  
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Of the 702 randomised women, 640 (92%) started an in vitro fertilisation treatment cycle (Figure 1). 
The two study groups were similar in the in vitro fertilisation cycle characteristics (Table 3).  
 
The live birth rate was 29% (102/350) in the hysteroscopy group and 29% (102/352) in the control 
group (RR 1·0, 95% CI 0·79, 1·25, P=0·96, table 4). The twin birth rate was 25% (25/102) in the 
hysteroscopy group and 28% (28/102, P=0·63) in the control group. There was no statistically 
significant heterogeneity in the live birth rate between the two groups amongst the eight hospitals 
participating in the trial (I2 test of heterogeneity = 0%, P=0·62, figure 2). There was no statistically 
significant difference in the likelihood of a live birth between the two groups after adjusting for 
participants’ age, body mass index, basal follicle stimulating hormone level, number of previous 
failed in vitro fertilisation treatment cycles and participating centre (adjusted RR 0·99, 95% CI 0·79, 
1·24, P=0·95). 
 
The pregnancy rate was 38% (133/350) in the hysteroscopy group and 39% (136/352) in the control 
group (RR 0·97, 95% CI 0·72, 1·32, P=0·86). The clinical pregnancy rate was 35% (121/350) in the 
hysteroscopy group and 33% (116/352) in the control group (RR 1·08, 95% CI 0·79, 1·47, P=0·65, 
table 4). The implantation rate was 29% in the hysteroscopy group and 30% in the control group in 
cycles reaching embryo transfer (RR 0.91, 95% CI 0·61, 1·37), and 32% in the hysteroscopy group 
and 32% in the control group in cycles where at least one top quality embryo was transferred (RR 1·0, 
95% CI 0·65, 1·56). The overall pregnancy loss rate in the study was 25% (66/269), which included 
one ectopic pregnancy in the hysteroscopy group and two second-trimester pregnancy terminations 
due to severe fetal malformation (one in each group). The miscarriage rate was 22% (29/131) in the 
hysteroscopy group and 24% (33/135) in the control group (RR 0·91, 95% CI 0·59, 1·40, P=0·65).  
 
Ten of the 301 women who received embryo transfer in the hysteroscopy group declined 
hysteroscopy (Figure 1). In the control group, four of the 290 women who received embryo transfer 
underwent hysteroscopy before starting the in vitro fertilisation cycle. Thus, a per-protocol analysis 
included 295 women in the hysteroscopy group and 296 women in the control group. According to 
that analysis, the live birth rate was 32% (94/295) in the hysteroscopy group and 33% (97/296) in the 
control group (RR 0·97, 95% CI 0·77, 1·23, P=0·81). 
 
The live birth rate was similar in the subgroup of women who had a normal hysteroscopy (28%, 
66/238) and in those who had an abnormal hysteroscopy (30%, 26/85), compared to the live birth rate 
in the control group (RR 0·96, 95% CI 0·74, 1·24, P=0·74, and RR 1·06, 95% CI 0·74, 1·51, P=0·76, 
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respectively). The live birth rate in the subgroup of women in whom a subtle endometrial abnormality 
was reported at hysteroscopy was 33% (14/41). 
 
The live birth rate was similar in the subgroups of women who had two previous failed in vitro 
fertilisation treatment cycles in the hysteroscopy (28·4%, 52/183) and control (27%, 51/189) groups 
(RR 1·05, 95% CI 0·76, 1·46, P=0·75), and in those who had at least three previous failed in vitro 
fertilisation treatment cycles in the hysteroscopy (30%, 50/167) and control (31·3%, 51/163) groups 
(RR 0·96, 95% CI 0.69, 1·32, P=0·79). 
 
Among women who did not report a history of undergoing a hysteroscopy over two months before 
randomisation, the live birth rate was 34% (65/193) in the hysteroscopy group and 31% (61/198) in 
the control group (RR 1·09, 95% CI 0·82, 1·46, interaction test P=0.48). 
 
Discussion: 
This large multi-centre allocation concealed randomised trial showed that routine outpatient 
hysteroscopy performed before starting an in vitro fertilisation treatment cycle in women who had 
normal ultrasound scan of the uterine cavity and a history of recurrent implantation failure does not 
improve treatment outcome. The study results do not support earlier suggestions that outpatient 
hysteroscopy could improve the success rate of in vitro fertilisation treatment, even when 
hysteroscopy reveals normal findings. We found no difference in the live birth rate after in vitro 
fertilisation treatment in women who had a normal hysteroscopy compared with women who had no 
hysteroscopy.  
 
Previous studies have hypothesised that the beneficial effect of hysteroscopy on in vitro fertilisation 
outcome could be mediated through the treatment of unsuspected uterine pathology identified at 
hysteroscopy.21 Our study identified cervical or uterine cavity abnormalities in 26% of the 
hysteroscopies performed. However, in two-thirds (57/85) of these hysteroscopies, the reported 
abnormalities were not treated, because they were considered either untreatable, such as deviated or 
shortened cervical canal and hemi-uterus, or of undetermined clinical significance, such as 
dysmorphic (arcuate) uterine cavity and subtle endometrial abnormality.22  Given the small number of 
uterine cavity abnormalities treated in the hysteroscopy group, the role of hysteroscopic correction of 
specific uterine cavity abnormalities in improving in vitro fertilisation outcome could not be 
determined based on the study results. Therefore, future research in which assessment of the uterine 
cavity is needed could include 3D ultrasound scanning in order to address the effectiveness of surgical 
correction of specific uterine cavity abnormalities before in vitro fertilisation treatment, and develop 
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universally-agreed guidelines to improve inter-observer agreement on the diagnosis of such 
abnormalities to further refine clinical practice. 23-25  
 
Hysteroscopy has been proposed to improve in vitro fertilisation outcome by stimulation of the 
endometrium through surface injury. This has been suggested to increase the likelihood of embryo 
implantation in the subsequent in vitro fertilisation treatment cycle.26,27 Endometrial injury is not a 
routine step of outpatient hysteroscopy and could be performed without hysteroscopic guidance. It is 
plausible that the smaller diameter of the hysterocope used in our study (2·9mm), compared to the 
diameter of the hysterscopes used in previous studies (5mm), had caused less endometrial surface 
injury, resulting in a milder degree of endometrial stimulation for implantation. Nevertheless, this 
may not be a significant factor in light of recent evidence,28,29  although further research is still 
required in this area. 
 
It has also been postulated that since a difficult embryo transfer procedure could compromise in vitro 
fertilisation outcome, performing a hysteroscopy before starting a treatment cycle could facilitate 
future embryo transfer, via amelioration of cervical canal obstruction and optimisation of embryo 
transfer procedure, and thus improve treatment outcome.15 Our study was the first randomised trial to 
record the clinician’s assessment of the ease of the embryo transfer procedure in women with 
recurrent implantation failure, and found similar percentage of easy embryo transfer procedures in the 
two study groups (93% vs 94%).  
 
In this study, 44% of women had a history of previously undergoing a hysteroscopy over two months 
before recruitment into the trial, which could account for the low prevalence of treatable uterine 
cavity abnormalities in the hysteroscopy group. It could be argued that those who did not have a 
history of previous hysteroscopy could benefit most from the procedure when performed just before 
starting the in vitro fertilisation treatment cycle. However, there was no significant difference in the 
live birth rate between the two study groups amongst those who did not have a history of previous 
hysteroscopy prior to recruitment into the trial, thus re-enforcing the main study results. This 
observation warrants further investigation in future studies.  
 
The TROPHY trial has several strengths. In addition to the large number of women recruited into the 
trial, it addressed the substantive methodological limitations of previously published studies, via its 
multicentre design, robust randomisation and allocation concealment to eliminate selection bias,30 and 
minimisation for key prognostic factors to achieve balanced treatment allocation at baseline. 
Important confounding variables such as duration of infertility, smoking habits, presence of uterine 
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fibroids, pre-treatment antral follicle count and in vitro fertilisation treatment cycle characteristics, 
were similarly distributed between the two study groups. Blinding of the embryologists involved in 
the embryo transfer procedure to the assignment of the treatment group was employed to reduce 
performance bias. Furthermore, the multi-country design of the study ensured that the results are 
applicable to different in vitro fertilisation settings, thus enhancing the generalisability and validity of 
the study conclusions. 
 
In summary, it is important that routine interventions before in vitro fertilisation treatment are 
supported by robust evidence of effectiveness. The TROPHY study demonstrates that outpatient 
hysteroscopy in the month before starting an in vitro fertilisation treatment cycle in women younger 
than 38 years with normal ultrasound scan of the uterine cavity and history of two to four failed in 
vitro fertilisation treatment cycles does not increase the live birth rate. 
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Table 1. Baseline patient demographic characteristics. Results are given as % (n/N) unless otherwise 
stated.  
Characteristic Hysteroscopy group Control group 
Mean (±SD*) female age at randomisation 
(range 23-37 years) 
32·7 ± 3·1 32·7 ± 3·1 
Female age ≥30 years  
<30 years 
30-35 years 
>35 years 
82·6 % (289/350) 
17·4 % 
58·3 % 
24·3 %  
83·8 % (295/352) 
16·2 % 
62·2 % 
21·6 % 
Mean (±SD) female body mass index at 
randomisation (range 17-35) 
23·4 ± 3·5 23·3 ± 3·4 
Female body mass index 30-35 kg/m2 4·6 % (16/350) 4·8 % (17/352) 
Female smoking status 4·6 % (16/350) 3·7 % (13/352) 
Mean (±SD) duration of infertility, years 4·2 ± 3·4 4·2 ± 2·8 
Cause of Infertility 
Male factor 
Tubal Factor 
Anovulation 
Endometriosis 
Combined 
Unexplained 
 
45 % (157/350) 
17 % (61/350) 
6% (21/350) 
11 % (39/350) 
6 % (20/350) 
15% (52/350) 
 
45 % (159/352) 
15 % (53/352) 
7 % (26/352) 
7 % (26/352) 
7 % (26/352) 
18 % (62/352) 
Previous pregnancy 
Previous live birth 
35% (123/350) 
10 % (34/350) 
35% (122/352) 
11 % (37/352) 
Mean (±SD) number of previous failed IVF 
cycles 
Mean (±SD) failed fresh IVF cycles 
Mean (±SD) failed frozen IVF cycles 
2·7 ± 0·9 
 
1·9 ± 0·8 
0·8 ± 0·8 
2·7 ± 1·0 
 
1·9 ± 0·7 
0·9 ± 0·9 
Presence of uterine fibroids 
   intramural   
   subserosal 
   intramural and subserosal 
Mean largest diameter of fibroid (SD) mm 
4% (15/350) 
6/15 
7/15 
2/15 
22·3 (13·4) 
4 %  (14/352) 
7/14 
6/14 
1/14 
23·7 (18·1) 
Mean basal follicle stimulating hormone 
level iu/L (range 1-16) 
Basal follicle stimulating hormone level 
≥10 iu/L 
6·1 ± 2·4 
 
5 % (17/350) 
6·3 ± 2·5 
 
5 % (18/352) 
Mean antral Follicle count§ 15 ± 7 16 ± 8 
Previous hysteroscopy 45 % (157/350) 44 % (154/352) 
Previous uterine surgery 
Myomectomy 
Caesarean section 
Correction of congenital anomaly 
Removal of conception products 
Removal of polyp(s) or scarring 
Cervical dilation, cauterisation or excision 
of transformation zone 
6·3 % (22/350) 
6 
2 
2 
1 
4 
7 
6·5 % (23/352) 
4 
2 
3 
2 
6 
                 6 
* SD denotes standard deviation  
§ Estimates checked by boot-strapping and no important difference found. 
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Table 2. Abnormal hysteroscopic findings in the hysteroscopy group. 
 
 
Hysteroscopic finding Number 
Cervical abnormalities (4%, 14/323) 
Stenosis of external os 
Stenosis of internal os 
Cervical canal adhesions 
Cervical canal deviation (retroversion)  
Polyp 
Shortened cervical canal 
 
3 
4 
3 
2 
1 
1 
Uterine cavity abnormality (10.5%, 34/323) 
Dysmorphic (arcuate) cavity 
Hemi-uterus 
Endometrial polyp(s) 
Partial uterine septum 
Submucous fibroid 
T-shaped uterine cavity 
 
15 
3 
8 
5 
2 
1 
Subtle endometrial abnormality (11.5%, 37/323) 
Hypervascularisation 
Mucosal elevation 
Micro-polyps 
Pale endometrium 
Endometrial defect 
Single adhesion band 
 
20* 
12 
3 
3 
2 
1 
 * four patients also had dysmorphic (arcuate) uterus 
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Table 3. In vitro fertilisation cycle and embryologic characteristics. Results are given as % (n/N) 
unless otherwise stated.  
 
IVF cycle feature 
 
Hysteroscopy Control group Mean difference 
(95% CI*) 
P-
value 
IVF treatment protocol 
Long GnRH agonist 
Short GnRH agonist 
Short GnRH antagonist 
Other 
 
48 % (156/322) 
14 % (45/322) 
35 % (112/322) 
3 % (9/322) 
 
50 % (158/318) 
16 % (50/318) 
30 % (97/318) 
4 % (13/318) 
  
Percentage of cycles using 
recombinant gonadotrophins 
62% 67%  0·21 
Mean (±SD) total dose of 
gonadotrophins used 
2425 ± 1335 2281 ± 1269 144 (-57, 344) 0·16 
Mean (±SD) number of 
oocytes retrieved 
10·5 ± 5·6 10·5 ± 6·1 -0·06 (-1·0, 0·89) 0·91 
Percentage of cycles using 
ICSI for oocyte fertilisation 
78% 78%  0·84 
Mean (±SD) number of 
oocytes fertilised normally 
6·1 ± 4·0 5·8 ± 4·1 0·23 (-0·42, 
0·88) 
0·49 
Number of IVF cycles 
reaching embryo transfer  
301 290   
Mean number of embryos 
transferred  
   1 embryo transferred 
   2 embryos transferred 
   3 embryos transferred 
1·8 ± 0·5 
 
26% (78/301) 
70% (212/301) 
4% (11/301) 
1·8 ± 0·5 
 
26% (75/290) 
70% (203/290) 
4% (12/290) 
0·02 (-0·10, 
0·06) 
0·66 
Day of embryo transfer 
Day 2 
Day 3§ 
Day 5/6 
Not known 
 
24 % (73/301) 
35 % (104/301) 
40 % (120/301) 
1 % (4/301) 
 
24 % (70/290) 
35 % (99/290) 
40 % (118/290) 
1 % (3/290) 
  
Easy embryo transferα 93% (280/301) 94% (271/290) -0·4 (-2·4, 8·9) 0·83 
 
Embryo transfers with at 
least one top quality embryo¶ 
77% (232/301) 79% (236/290) -2% (-8, 5) 0·58 
Cycles with surplus embryos 
frozen 
45% (137/301) 41% (118/290) -4% (-3·4, 12·4) 0·26 
 
* CI denotes confidence interval 
§  Including embryo transfer on day 4  
α Defined as a straightforward transfer without encountering any difficulty or requiring the use of rigid 
stylet or application of a volsellum 
¶ An embryo was considered of top quality if it had four cells on day 2 or seven to eight cells on day 3, 
with even cell size and no or less than 10% cytoplasmic fragmentation by volume, or if it had reached 
the expanded blastocyst stage on day 5 or 6 after fertilization with prominent and compact inner cell 
mass and many identical trophectoderm cells forming a continuous layer19 
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Table 4.  Rates of pregnancy and live birth in the two study groups. Results are given as % (no.).  
 
Variable Hysteroscopy group 
 
Control group Relative risk (95% CI*) P-value 
Rate / patient 
randomly 
assigned to 
intervention 
N=350 
 
% (no.) 
N=352 
 
% (no.) 
  
Pregnancy 38 (133) 39 (136) 0·97 (0·72, 1·32) 
 
0·86 
Clinical 
pregnancy 
35 (121) 33 (116) 1·08 (0·79, 1·47) 0·65 
Live birth 29 (102) 29 (102) 1·0 (0·79, 1·25) 
 
0·96 
Rate / patient 
receiving 
embryo 
transfer 
N=301 
 
% (no.) 
N=290 
 
% (no.) 
  
Pregnancy 42 (125) 44 (128) 0·94 (0·78, 1·13) 
 
0·52 
Clinical 
pregnancy 
38 (114) 38 (110) 0·99 (0·81, 1·22) 0·99 
Live birth 32 (95) 33 (96) 0·95 (0·76, 1·20) 
 
0·69 
Rate / patient 
receiving at 
least one top 
quality 
embryo  
N=232 
 
% (no.) 
N=236 
 
% (no.) 
  
Pregnancy 45 (104) 46 (109) 0·97 (0·80, 1·18) 
 
0·77 
Clinical 
pregnancy 
42 (97) 42 (98) 1·01 (0·84, 1·21) 0·99 
Live birth 35 (82) 36 (86) 0·98 (0·81, 1·24) 
 
0·81 
 
* CI denotes confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
